However, class II (28% vs. 6.8%, p < 0.001) and class III (23% vs. 14%, p < 0.001) were more commonly seen in BRAF-altered non-CRC GI malignancies compared to BRAF-altered CRC. Here, BRAF is linked to colorectal carcinoma.